CAVERJECT Drug Patent Profile

When do Caverject patents expire, and when can generic versions of Caverject launch?

Caverject is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Caverject

A generic version of CAVERJECT was approved as alprostadil by HIKMA on January 20^th, 1998.

Summary for CAVERJECT

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	2
Patent Applications:	3,482
Drug Prices:	Drug price information for CAVERJECT
What excipients (inactive ingredients) are in CAVERJECT?	CAVERJECT excipients list
DailyMed Link:	CAVERJECT at DailyMed

See drug prices for CAVERJECT

Recent Clinical Trials for CAVERJECT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari	NA
City of Hope Medical Center	Phase 3

See all CAVERJECT clinical trials

Pharmacology for CAVERJECT

Drug Class	Prostaglandin Analog Prostaglandin E1 Agonist
Mechanism of Action	Prostaglandin Receptor Agonists
Physiological Effect	Genitourinary Arterial Vasodilation Venous Vasodilation

US Patents and Regulatory Information for CAVERJECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-003	Jun 27, 1996		DISCN	Yes	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-004	May 19, 1997	AP	RX	Yes	Yes
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-002	Oct 1, 1997		DISCN	No	No
Pfizer	CAVERJECT IMPULSE	alprostadil	INJECTABLE;INJECTION	021212-001	Jun 11, 2002		RX	No	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020755-001	Oct 31, 1997		DISCN	No	No
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-001	Jul 6, 1995	AP	RX	Yes	No

Expired US Patents for CAVERJECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-003	Jun 27, 1996	5,741,523
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-004	May 19, 1997	5,741,523
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-001	Jul 6, 1995	4,127,118
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-002	Jul 6, 1995	5,741,523
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-002	Jul 6, 1995	4,127,118
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-001	Jul 6, 1995	5,741,523

International Patents for CAVERJECT

See the table below for patents covering CAVERJECT around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	725642
Norway	309126
Denmark	0725642
Austria	187071
Finland	961797
European Patent Office	0725642	PROSTAGLANDINE E 1 STABILISEE (STABILIZED PROSTAGLANDIN E 1)

Market Dynamics and Financial Trajectory for CAVERJECT

Last updated: February 12, 2026

Overview
CAVERJECT (alprostadil for injection) is a prescription-only medication used to treat erectile dysfunction (ED). Approved by the FDA in 1995, CAVERJECT has maintained a niche presence within the ED treatment market, primarily through its unique intracavernosal injection route. Its market trajectory depends on competitive landscape shifts, patent protections, and evolving treatment preferences.

Market Size and Revenue Trends
Globally, ED affects approximately 150 million men, with the U.S. accounting for the largest share of prescriptions. The ED market was valued at around $1.8 billion in 2022, with CAVERJECT holding an estimated 15-20% share.[1] Sales peaked around 2010 at approximately $330 million in the U.S., driven by high efficacy perceptions and physician familiarity.

From 2015 onward, revenues declined modestly, reflecting increased competition from oral PDE5 inhibitors (e.g., sildenafil, tadalafil) that gained popularity due to ease of use. As of 2022, annual sales hovered near $150 million globally, with U.S. sales around $125 million. The decline stems from market saturation and patient preference shifts towards oral therapies.

Patent and Regulatory Status
CAVERJECT's patents expired in 2016, opening the market to biosimilars and generic formulations. The availability of generics has further pressured pricing, resulting in lower per-unit costs and reduced margins. The original formulation remains protected by exclusivity rights in some jurisdictions until 2024-2026 due to secondary patents and manufacturing processes.

The drug’s route of administration—intracavernosal injection—limits its acceptance despite demonstrated efficacy. Regulatory pathways for alternative delivery methods (e.g., topical formulations) are under exploration but face technical hurdles.

Competitive Landscape
CAVERJECT competes primarily with oral PDE5 inhibitors. Its key advantages are in cases of contraindications or non-response to oral agents. The market now includes alternatives such as:

• Vitaros (alprostadil cream): Approved in some regions as a topical alternative.
• Muse (alprostadil urethral suppository): Limited to specific markets; offers a less invasive route.
• Biosimilars and generics: Entered post-patent expiry, exerting downward pressure on prices.

Emerging therapies, including gene therapy and implantable devices, could disrupt the current landscape if approved.

Financial Outlook and Drivers
Projected revenues for CAVERJECT are expected to decline by approximately 5-10% annually over the next five years, driven by:

• Market saturation with PDE5 inhibitors.
• Increasing availability of generics reducing price points.
• Limited innovation within the intracavernosal injection space.
• Growing patient preference for oral medications.

Manufacturers may attempt to maintain margins through cost reductions or by expanding indications, such as for Peyronie’s disease or vascular conditions. However, these efforts face regulatory and clinical validation challenges.

Key Factors Impacting Future Trajectory

Factor	Impact	Status
Patent expiration	Entry of generics, price erosion	Active since 2016
New delivery modalities	Potential to replace injections	Under development
Competition from oral PDE5 inhibitors	Reduces market share for injection products	Ongoing
Clinical trials for new indications	Potential revenue expansion if approved	Limited, ongoing

Conclusion
CAVERJECT's market presence will continue to diminish absent significant innovations or broader indication approvals. Its niche role in ED treatment persists primarily among specific patient subsets, but from a revenue perspective, the outlook suggests steady decline aligned with market trends.

---

Key Takeaways

• CAVERJECT sales peaked in the early 2010s, with a current global estimate near $150 million annually.
• Patent expiration in 2016 led to increased generic competition and prolonged pricing pressures.
• The shift toward oral ED therapies reduces the pool of patients opting for injection-based treatment.
• Market growth prospects hinge on new formulation developments, alternative delivery methods, and expanded uses.
• Long-term revenue decline is expected unless drug innovation or new indications emerge.

---

FAQs

1. How does CAVERJECT compare with oral ED medications?
CAVERJECT is administered via intracavernosal injection, offering a treatment option when oral PDE5 inhibitors are contraindicated or ineffective. Its efficacy is high, but it involves injections, which limits patient acceptance. Oral medications are preferred for convenience but may be less suitable for certain patients.

2. What is the impact of patent expiration on CAVERJECT?
Patent expiry in 2016 facilitated generic entry, leading to lower prices and reduced revenue for the original manufacturer. The loss of patent protection diminishes exclusivity and sales potential unless new formulations or indications are developed.

3. Are there ongoing developments to replace injections?
Yes. Researchers are exploring topical formulations like alprostadil cream and alternative devices to deliver treatment non-invasively. However, these remain under development or limited regional approval.

4. How might biosimilars influence future revenues?
Biosimilars can reduce costs and expand access. Post-patent expiry, biosimilars have already entered some markets. Their presence tends to further compress prices and margins for the original product.

5. What other markets or indications could sustain CAVERJECT's revenue?
Potential expansion into treatments for Peyronie’s disease, vascular conditions, or other sexual dysfunctions might provide revenue streams. Regulatory approval and clinical validation are prerequisites for such extensions.

---

References
[1] Market data sourced from IQVIA and EvaluatePharma reports (2022).